BridgeBio Oncology Therapeutics, Inc(BBOT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBOT BridgeBio Oncology Therapeutics, Inc

休市中 09-11 16:00:00 EDT

4.95

-0.57

-10.33%

盘后4.94

-0.01-0.20%

19:30 EDT

最高5.62	最低4.90	成交量163.10万
今开5.53	昨收5.52	日振幅12.97%
总市值3.96亿	流通市值1.77亿	总股本7,999万
成交额827.69万	换手率4.56%	流通股本3,575万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":4.95,"timestamp":1789156800000,"preClose":5.52,"halted":0,"volume":1631034,"hourTrading":{"tag":"盘后","latestPrice":4.94,"preClose":4.95,"latestTime":"19:30 EDT","volume":971,"amount":4811.43765,"timestamp":1789169406765,"change":-0.01,"changeRate":-0.00202,"amplitude":0.00202},"delay":0,"changeRate":-0.1032608695652173,"floatShares":35752400,"shares":79988687,"eps":-2.273,"marketStatus":"休市中","change":-0.57,"latestTime":"09-11 16:00:00 EDT","open":5.53,"high":5.616,"low":4.9,"amount":8276939.736372001,"amplitude":0.12971,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.273,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":5.52,"preHourTrading":{"tag":"盘前","latestPrice":5.67,"preClose":5.52,"latestTime":"09:29 EDT","volume":5403,"amount":29674.0518708,"timestamp":1789133360032,"change":0.15,"changeRate":0.027174,"amplitude":0.056159},"postHourTrading":{"tag":"盘后","latestPrice":4.94,"preClose":4.95,"latestTime":"19:30 EDT","volume":971,"amount":4811.43765,"timestamp":1789169406765,"change":-0.01,"changeRate":-0.00202,"amplitude":0.00202},"volumeRatio":1.7347594296890443},"requestUrl":"/m/hq/s/BBOT","defaultTab":"news","newsList":[{"id":"1172791094","title":"BridgeBio Oncology Therapeutics：Bbo-11818与Bbo-10203单药治疗数据更新预计于2026年第四季度发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1172791094","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172791094?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:07","pubTimestamp":1788898029,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics今日宣布，其两款在研药物——Bbo-11818与Bbo-10203的单药治疗数据更新，预计将于2026年第四季度对外公布。值得注意的是，单药治疗的疗效与安全性数据，往往是评估药物潜力的基石。此番更新，不仅关乎BridgeBio在肿瘤学领域的战略布局，亦可能对相关治疗领域的竞争格局产生微妙影响。市场对此期待颇高，而数据的最终呈现，无疑将成为2026年末医药板块的焦点事件之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111874945","title":"Bbot发布Bbo-8520新数据，聚焦Kras突变癌症中Bbo-8520组合（2L+ NSCLC）及Bbo-11818与Bbo-10203组合的战略重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1111874945","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111874945?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:06","pubTimestamp":1788897977,"startTime":"0","endTime":"0","summary":"Bbot正式公布了其Bbo-8520的最新研究数据，同时明确揭示了公司在肿瘤管线布局上的核心战略方向。值得关注的是，这一战略高度聚焦于二线及以后（2L+）非小细胞肺癌领域的Bbo-8520联合疗法，并将目光延伸至KRAS突变相关癌症中，着力推动Bbo-11818与Bbo-10203的组合方案。从管线排序来看，Bbo-8520在NSCLC 2L+场景中的组合策略被置于首要位置，显示出公司对该适应症临床需求缺口的高度重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177819577","title":"摩根大通首予BridgeBio Oncology Therapeutics增持评级，目标价27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177819577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177819577?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:38","pubTimestamp":1783510691,"startTime":"0","endTime":"0","summary":"摩根大通发布研究报告，首次将BridgeBio Oncology Therapeutics, Inc纳入覆盖范围，并给予其“增持”评级。该投行为该股设定了27美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197660362","title":"BridgeBio Oncology Therapeutics公布2026年第一季度财报及公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1197660362","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197660362?lang=zh_cn&edition=full","pubTime":"2026-05-13 06:09","pubTimestamp":1778623778,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc. 发布了其2026年第一季度的财务业绩，并同步更新了公司运营的最新进展。根据报告，公司目前的现金储备预计足以支持其运营持续至2028年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194150244","title":"BridgeBio子公司Bbot获美国FDA快速通道资格 Bbo-11818用于治疗晚期KRAS突变胰腺导管腺癌成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1194150244","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194150244?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715708,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc（简称Bbot）宣布，其针对晚期KRAS突变胰腺导管腺癌成人患者的创新疗法Bbo-11818，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一认定将加速该候选药物的研发和审评进程，为存在迫切未满足医疗需求的患者群体带来新的治疗希望。\n胰腺导管腺癌作为最常见的胰腺癌类型，其KRAS突变亚型长期以来缺乏有效靶向治疗方案。快速通道资格的获得，不仅体现了Bbo-11818在早期研究中展现出的治疗潜力，也意味着该药物在后续临床试验中可获得与FDA更频繁的沟通交流机会，有望更快推进至上市申请阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181220084","title":"BridgeBio Oncology Therapeutics, Inc：更新版一期临床数据预计将于2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1181220084","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181220084?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715701,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc 近日透露，其备受关注的一期临床试验更新数据预计在2026年下半年揭晓。这一时间表的公布，为关注该公司研发进展的投资者与行业观察者提供了明确预期。\n此次数据更新对于评估相关候选药物的安全性与初步疗效具有关键意义。公司研发管线的最新动态，或将影响其未来的临床开发策略与市场定位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bbotx.com;investors.bbotx.com","stockEarnings":[{"period":"1week","weight":-0.4488},{"period":"1month","weight":-0.4745},{"period":"3month","weight":-0.3613},{"period":"6month","weight":-0.4554},{"period":"1year","weight":-0.5133},{"period":"ytd","weight":-0.6046}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Oncology Therapeutics, Inc.于2021年6月15日作为开曼群岛豁免公司注册成立。自2025年8月12日起，该公司完成了先前宣布的业务合并，合并后的公司注册地位于特拉华州。BBOT是一家临床阶段的生物技术公司，其使命是在RAS和PI3K α这两种最常发生突变的癌基因的驱动下改变癌症患者的生活。","exchange":"NASDAQ","name":"BridgeBio Oncology Therapeutics, Inc","nameEN":"BridgeBio Oncology Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Oncology Therapeutics, Inc(BBOT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Oncology Therapeutics, Inc(BBOT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Oncology Therapeutics, Inc,BBOT,BridgeBio Oncology Therapeutics, Inc股票,BridgeBio Oncology Therapeutics, Inc股票老虎,BridgeBio Oncology Therapeutics, Inc股票老虎国际,BridgeBio Oncology Therapeutics, Inc行情,BridgeBio Oncology Therapeutics, Inc股票行情,BridgeBio Oncology Therapeutics, Inc股价,BridgeBio Oncology Therapeutics, Inc股市,BridgeBio Oncology Therapeutics, Inc股票价格,BridgeBio Oncology Therapeutics, Inc股票交易,BridgeBio Oncology Therapeutics, Inc股票购买,BridgeBio Oncology Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Oncology Therapeutics, Inc(BBOT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Oncology Therapeutics, Inc(BBOT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}